The patent describes gene sequences, which have already been tested as HIV vaccine candidates in a Phase I clinical trial. Currently, the gene sequences are tested in a Phase I/II trial by the EuroVacc Foundation. As a licensor, Geneart provides the patented gene sequences for these trials.